BioSpace News Archive

IFM Therapeutics (IFM), a privately held biopharmaceutical company focused on developing therapies that modulate novel targets in the innate immune system, announced today that Novartis has exercised its option to acquire all of the outstanding capital stock of IFM Due, a subsidiary company of IFM.

AstraZeneca today announced the initiation of a Phase III trial to investigate the potential effect of triple-combination inhaled therapy BREZTRI AEROSPHERE®.

Dyne Therapeutics, Inc. announced that management is scheduled to participate in a fireside chat at the Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 at 8:30 a.m. ET.

Indaptus Therapeutics, Inc. announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.

Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Ocugen, Inc. today announced that dosing is complete in the first cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV- hRORA )—a modifier gene therapy candidate being developed for geographic atrophy (GA), an advanced stage of dry age related macular degeneration (dAMD).

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D), today reported financial results for the fourth quarter and year ended December 31, 2023, and provided an update on recent corporate developments.

Kazia Therapeutics Limited is pleased to announce the presentation of new data for both its pipeline molecules, paxalisib and EVT801, at the upcoming Annual Meeting of the American Association of Cancer Research (AACR) in San Diego, California, from 5-10 April 2024.

RG6501 (OpRegen ® ) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit.

Fabric Genomics is announcing a new partnership with Intermountain Children’s Health to analyze the whole genomes of children sequenced by the Broad Clinical Labs to help speed diagnosis of kids who may have genetic diseases.